The Food and Drug Administration is on a roll. America’s drug regulator recently approved Veopoz as the first treatment for Chaple disease, a very rare inherited immune condition. The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial […]. Read More in Red Pill NOWlej.
